Rezolute Stock
Rezolute, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Nevan Charles Elam
- Employees
- 58
- Market cap
- $346 M
- IPO
- 14/01/2013
Rezolute, Inc. (RZLT) specializes in the healthcare/biotechnology sector, focusing on treating rare diseases such as hypoglycemia caused by hyperinsulinism. The Redwood City-based US company focuses its research primarily on the clinical asset ersodetug. This monoclonal antibody is currently in Phase 3 clinical trials…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Rezolute stock: price history
1D
-8.2%
1W
-26.5%
1M
-10.1%
6M
+3.5%
YTD
+51.7%
1Y
-59.6%
2Y
-27.7%
5Y
-46.2%
10Y
-94.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~50% weaker price swings than usual
Rezolute stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Rezolute, Inc. is a specialized biotechnology company focused on rare diseases, with a particular emphasis on treating hypoglycemia resulting from hyperinsulinism. The company is at an advanced stage of clinical research and primarily concentrates on developing the monoclonal antibody ersodetug. This therapeutic agent is currently being investigated in Phase 3 studies for the treatment of congenital hyperinsulinism as well as for tumor hyperinsulinism. The business model aims at commercializing specialized therapies for ultra-rare pediatric genetic disorders, with the current focus strongly centered on clinical development and validation of the lead product.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Rezolute
Analyst assessment of Rezolute
PRICE TARGET LOW
US$6.00
CONSENSUS
US$9.17
MEDIAN
US$8.50
PRICE TARGET HIGH
US$14.00
0
STRONG BUY
14
BUY
0
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 06/10/2026
Rezolute stock metrics
P/E
-4.71
P/B
3.72
EV/EBITDA
-4.28
RETURN ON EQUITY
-20.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.0%
FLOAT SHARES
60,902,184
AVG. DAILY VOLUME (30D)
1,738,843
Insider transactions (SEC)
Karnawat Sunil Ratilal
Evans Daron
Elam Nevan C
ROBERTS BRIAN KENNETH
Attention
Price since yesterday: -8.2%
Viel Aufmerksamkeit bei schwachem Qualitätsscore.
Elevated volatility risk.
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Rezolute stock
What does Rezolute do?
Rezolute, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Nevan Charles Elam, the company employs around 58 people.
The IPO was on 14/01/2013; the stock trades on NASDAQ under the ticker RZLT.
What do analysts say about Rezolute stock?
14 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$9.17, ranging from US$6.00 to US$14.00, with a median of US$8.50.
This is an external assessment, not a statement by Market Jury.
When does Rezolute report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -50% stronger than usual.
Does Rezolute pay a dividend?
No, Rezolute currently does not pay a dividend.
Which stocks are comparable to Rezolute?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rezolute stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rezolute against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.